Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AssigneeWyeth
InventorsAbdolsamad TADAYON, Silvio IERA, Mahmoud MIRMEHRABI
Life of this patent
Estimating the term…
Abstract
The present invention is directed to an anhydrate crystal form (designated as Form B herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.
Claims39
An anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at about 8.5°, about 10.8°, and about 15.3°.
An anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol having a differential scanning calorimetry trace comprising a melting endotherm having an onset at about 246° C.
An anhydrate crystal form (Form B) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol having a thermogravimetric analysis profile showing less than about 1% weight loss from about 30 to about 150° C.
Dependencies are inferred from the claim text.